Le Lézard
Classified in: Health, Business
Subject: LIC

AcuCort is granted SME status by the European Medicines Agency, EMA

STOCKHOLM, June 27, 2022 /PRNewswire/ -- AcuCort AB (publ) (Spotlight Stock Market: ACUC) announces that the European Medicines Agency, EMA, has decided that the company meets the requirements for SME status in accordance with current EU regulations. The positive decision entails certain administrative and financial benefits for AcuCort in future applications for market approval for the company's pharmaceutical product ISICORT® within the EU.

During the spring, AcuCort applied to EMA aiming to qualify the company in the category micro, small or medium-sized enterprise (SME) laid down in Regulation (EC) No 2049/2005. EMA's positive decision confirms AcuCort's eligibility to benefit from the provisions for administrative and financial assistance for SMEs when applying for market approval within the EU. The achieved SME status is valid until December 31, 2023.

ISICORT® is a thin and small fast-soluble mouth film, containing the glucocorticoid dexamethasone, to put on the tongue where the active anti-inflammatory substance dexamethasone dissolves quickly and provides effective relief. ISICORT® is an approved drug in Sweden for the treatment of, among other things, acute and severe allergic reactions. Intensive work is underway with registration applications for other priority markets such as the EU and the United States.

"It is very gratifying that the European Medicines Agency has granted AcuCort SME status in the EU. Fees for market registrations are large costs for a company like AcuCort. Therefore, we truly welcome EMA's positive decision," says Jonas Jönmark, CEO of AcuCort.

Earlier this year, the U.S. Food and Drug Administration, FDA, granted AcuCort's application for exemption from the application fee via a so-called Small Business Waiver for the registration process of ISICORT® in the U.S.

The information was submitted for publication, through the agency of the contact person below, on June 27, 2022.


For more information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
Email: jonas.jonmark@acucort.se

This information was brought to you by Cision http://news.cision.com


The following files are available for download:


2022 06 27 press release_AcuCort is granted SME status by the European Medicines Agency EMA

These press releases may also interest you

at 19:15
iHire has been named to the annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. With revenue growth of 99.3% between 2018 to 2021, iHire earned a coveted spot on the list for the second straight...

at 19:10
Shawcor Ltd. ("Shawcor" or the "Company") today announced that its pipe coating division ("Pipeline Performance Group" or "PPG") has received a formal contract valued at approximately C$500 million from Transportadora de Gas Natural de la Huasteca,...

at 19:05
PrimeEnergy Resources Corporation announced today the following unaudited results for the periods ended June 30, 2022 and 2021:     Three Months Ended June 30,     Six Months Ended June 30,       2022     2021    ...

at 18:58
Ohio Valley Banc Corp. [Nasdaq: OVBC] (the "Company") announced the Board of Directors has authorized the extension date of its existing stock buyback program to August 31, 2023. The program was originally approved by the board in 2021 and was set to...

at 18:45
Purpose Investments Inc. ("Purpose") today announced corrections to the August 2022 distribution record date for Canadian Investment Grade Preferred Share Fund (NEO: RIGP.UN) and Big Banc Split Corp. ("the CEFs"). The press release issued on August...

at 18:45
TSX VENTURE COMPANIES AVANTI HELIUM CORP. ("AVN")[formerly Avanti Energy Inc. ("AVN")] BULLETIN TYPE:  Name ChangeBULLETIN DATE:  August 18, 2022 TSX Venture Tier 2 Company Pursuant to a Director's Resolution dated August 4, 2022, the Company has...

News published on 27 june 2022 at 08:12 and distributed by: